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Abstract 
Background 
Carcinogenic risks of internal exposures to alpha-emitters (except radon) are poorly 
understood. Since exposure to alpha particles—particularly through inhalation—occurs in a 
range of settings, understanding consequent risks is a public health priority. We aimed to 
quantify dose–response relationships between lung dose from alpha-emitters and lung cancer 
in nuclear workers. 
Methods 
We conducted a case–control study, nested within Belgian, French, and UK cohorts of 
uranium and plutonium workers. Cases were workers who died from lung cancer; one to three 
controls were matched to each. Lung doses from alpha-emitters were assessed using bioassay 
data. We estimated excess odds ratio (OR) of lung cancer per gray (Gy) of lung dose. 
Results 
The study comprised 553 cases and 1333 controls. Median positive total alpha lung dose was 
2.42mGy (mean: 8.13mGy; maximum: 316mGy); for plutonium the median was 1.27mGy 
and for uranium 2.17mGy. Excess OR/Gy (90% confidence interval)—adjusted for external 
radiation, socioeconomic status, and smoking—was 11 (2.6, 24) for total alpha dose, 50 (17, 
106) for plutonium, and 5.3 (-1.9, 18) for uranium. 
Conclusions 
We found strong evidence for associations between low doses from alpha-emitters and lung 
cancer risk. The excess OR/Gy was greater for plutonium than uranium, though confidence 
intervals overlap. Risk estimates were similar to those estimated previously in plutonium 
workers, and in uranium miners exposed to radon and its progeny. Expressed as 
risk/equivalent dose in sieverts (Sv), our estimates are somewhat larger than but consistent 
with those for atomic bomb survivors. 
AC
CE
PT
ED
Copyright © Wolters Kluwer Health, Inc. All rights reserved. Unauthorized reproduction of this article is prohibited.
6 
Introduction 
Background 
Knowledge of long-term health effects of ionizing radiation is chiefly derived from studies of 
populations exposed to photons (X and gamma rays), particularly the Japanese atomic bomb 
survivors
1
 and populations receiving external radiation doses through occupational, medical, 
and environmental exposures
2
. Less is known about long-term impacts of internal exposure to 
emitters of alpha particles. Since internal exposures to alpha-emitters occur in environmental, 
malicious, accidental, or occupational settings, understanding attendant long-term risks is a 
priority in radiation protection.  
The nuclear industry encompasses a range of activities e.g. energy and isotope production, 
fuel manufacturing and reprocessing, production of nuclear weapons, and research. 
Monitoring of external photon exposures is relatively straightforward and many cohorts have 
complete records from the industry’s inception. Previous epidemiologic studies of nuclear 
workers have chiefly examined associations between cancers and photon radiation exposure
3–
5
. However, at some facilities—particularly those involved in the fuel cycle and weapons 
production—workers may receive internal doses from incorporation of radionuclides, in 
particular uranium and plutonium, by inhalation, ingestion, or contamination of wounds. 
Following inhalation/incorporation, doses to organs or tissues depend on the 
radionuclide/element, its physicochemical form, and intake route
6
. Densely ionizing 
radiations such as alpha particles have a greater relative biologic effectiveness than sparsely 
ionizing radiation such as X and gamma rays for many cell toxicity endpoints. In radiological 
protection—where the prevention of cancer is generally the limiting factor—the increased 
relative biologic effectiveness of alpha particles is taken into account through the use of a 
radiation weighting factor (wR) of 20
7
. While sufficient evidence exists to classify internalized 
alpha-emitting radionuclides as carcinogenic, and there is sufficient evidence to declare some 
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radionuclides as human carcinogens (e.g. plutonium and radon progeny), data on risks at low 
doses are lacking for plutonium, and direct evidence of carcinogenicity in humans is limited 
for uranium
8
.  
Relatively large lung doses can result from inhaling uranium/plutonium, depending on lung 
solubilities of materials inhaled. Lung cancer risk from internal exposure to these 
radionuclides is therefore of interest. It is well established that prolonged exposure to radon 
progeny increases lung cancer risk
9,10
. Studies of cancer risks associated with plutonium have 
been conducted in highly-exposed individuals in the Mayak worker cohort (MWC)
11
 and less 
highly-exposed workers at Sellafield
12
, with uranium and plutonium in nuclear workers in the 
US
13–16
, and with thorium and radium in medical patients
17
. Dose–response analyses have 
been conducted on individually-assigned plutonium doses in Mayak and Sellafield cohorts. 
The MWC currently provides most of the information in humans on plutonium dose–response 
for several outcomes
18–22
 though it is limited by scant bioassay data and no monitoring in a 
substantial portion of the population. Dosimetry in the few other studies in which individual-
level lung doses from alpha-emitters have been reconstructed has largely been based on 
limited bioassay data, resulting in uncertain doses, particularly at low doses. 
An increased risk of solid cancer in relation to external radiation dose was found in the 
International Collaborative Study (ICS), a 15-country cohort study of nuclear workers
23,24
 and 
in the International Nuclear Workers Study (INWORKS), a continuation of the ICS restricted 
to USA, UK, and France
5
. The ICS excluded workers with potential for internal exposure to 
alpha-emitters as dose reconstruction was impracticable at the cohort level; smoking 
information was unavailable for the ICS and INWORKS. To complement these studies, and 
to address some limitations of MWC data, the current study was conducted to improve lung 
cancer risks associated with internal exposure to alpha-emitters, particularly at low doses, and 
to account for potential confounders e.g. smoking. Specifically, this study aimed to quantify 
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any dose–response relationship between cumulated lung dose from alpha-emitters and lung 
cancer mortality among nuclear workers monitored for uranium and/or plutonium exposure in 
five European cohorts. 
Methods 
Study design 
We conducted a case–control study of lung cancer mortality, nested in a set of five cohorts 
identified in the much larger ICS, comprising workers from Belgium, France, and the UK 
(Table 1). This design reduced data collection (internal monitoring and smoking) and 
individual dose reconstruction compared with a cohort study. Activities covered by these 
facilities include: nuclear research and development, waste treatment, fuel production and 
reprocessing, construction and operation of experimental reactors, development of fast 
breeder reactors, and nuclear weapons research and production. 
Study population 
The study population included all workers monitored for internal exposure to plutonium 
and/or uranium through urinalysis on or after a date, t1, and employed for ≥1 year at a facility 
in a study cohort. t1 was defined as the date after which bioassay (urine) data could be used to 
produce accurate and unbiased dose assessments (Table 1)
25
. For uranium, t1 often 
corresponded to the start of operation of a facility; for plutonium, early bioassay 
measurements were less reliable. Workers with only pre-t1 data were excluded. Workers 
employed for <1 year were excluded, as they may not be comparable to longer-term workers 
in terms of cancer risk. Contract workers were excluded as work histories and exposures 
could not be comprehensively reconstructed, and mortality could not be comprehensively 
followed up.  
We defined cases as all deaths within the study populations and mortality follow-up periods 
(Table 1) for which lung cancer was either the underlying cause of death or an associated 
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cause where no other cancer was listed as an underlying cause. Controls were alive and at risk 
in the year of death of the case (“reference date”); one to three controls were matched to each 
case by age at reference date (within 5 years), sex and facility (for cohorts with more than one 
geographically distinct facility, the facility was used as the matching variable). Controls born 
closest to the date of birth of the case were preferentially selected. Controls were eligible for 
reselection as a control for another case and for reselection as a case.  
Dosimetry 
We obtained individual annual external dose estimates based on personal dosimeters, 
compiled for each worker for the purposes of other epidemiologic studies
24,26
. We estimated 
individual lung doses from internally incorporated alpha-emitters—chiefly plutonium and 
uranium and some others (radium, actinium, thorium, curium, polonium, protactinium, and 
americium)—for each subject annually from start of potential exposure up to and including 
the reference date of the relevant case. Doses were reconstructed from bioassay data 
(primarily urinalysis but also fecal analysis and in vivo monitoring if available) using a 
common methodology developed and tested by the study dosimetry subcommittee as detailed 
elsewhere
25
. Start of potential exposure to plutonium and uranium was determined from work 
history records or set to just before the start of bioassay monitoring. Where study subjects had 
both pre- and post-t1 monitoring data during their work history, pre-t1 data were included and 
doses calculated for pre-t1 years. Long retention of plutonium and uranium in the body means 
that later more reliable bioassay data can provide information on earlier (pre-t1) exposures. 
For workers employed at more than one facility or several times at the same facility, we 
reconstructed dosimetric and occupational histories, with final dose assessments conducted at 
the facility of last employment.  
Calculated doses depended on assumptions regarding the physicochemical properties of the 
radioactive materials to which a worker was exposed, lung absorption characteristics, and 
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intake (exposure) regimes (acute or chronic). We generated four indices of internal dose: total 
alpha dose (all radionuclides); alpha dose from plutonium; alpha dose from uranium; and dose 
from other alpha-emitters.  
We estimated doses using the Human Respiratory Tract Model (HRTM)
27
, in which the lung 
is partitioned into three regions: bronchial (BB), bronchiolar (bb) and alveolar interstitial (AI). 
Doses were estimated to each region, and to the whole lung, because doses to these regions 
from radionuclide-bearing aerosols vary and the radiosensitivities of cells in these regions are 
assumed to differ. We estimated doses for four cell types: basal (BBbas) and secretory (BBsec) 
cells (BB region), Clara cells (bb region), and endothelial cells (AI region). We summed 
regional doses using weights of 1/3 for AI and bb regions and 1/6 for BBsec and BBbas sub-
regions
27
. This weighted lung dose has been used in epidemiologic studies of radon and its 
progeny
28
 and is extensively used in radiation protection
9
. Studies of MWC have used a 
different approach, wherein dose is calculated as total energy deposited in the lung divided by 
lung tissue mass. We estimated mass-averaged doses for sensitivity analysis (weights: 
BB=0.0006; bb=0.0017; AI=0.9977).  
Potential confounding 
Information was available on the matching variables—age, sex, and facility—and 
socioeconomic status (SES). Facility is important in controlling for potential occupational co-
exposures and geographically determined factors (e.g. natural background radiation). SES is a 
surrogate for lifestyle factors associated with cancer including smoking and diet. SES was 
assigned to each subject based on job title—either at time of hiring (France), last job 
(UKAEA, AWE), or job of longest duration (other cohorts). For AWE, Belgium, France, and 
UKAEA, we assigned SES according to a regrouping of the British Registrar General’s 
classification, from 1 (unskilled) to 4 (intermediate and professional)
29
. For BNFL, detailed 
classification was not possible so workers were assigned categories 5 and 6, indicating 
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“industrial” (paid weekly) and “non-industrial” (paid monthly) work, respectively (eTable 1; 
http://links.lww.com/EDE/B205); “non-industrial” included managerial, scientific, and 
clerical staff; “industrial” comprised the remainder. For sensitivity analysis, we recoded SES: 
categories 1, 2, and 5 were combined (lower SES), and categories 3, 4, and 6 were combined 
(higher SES). 
Smoking is the main risk factor for lung cancer and an important potential confounder in this 
study. The record-based nature of this study precluded collection of comprehensive 
information on lifetime smoking status. Smoking information was extracted from 
occupational medical records from routine medical examinations. For Belgium and AWE, 
smoking information was well documented for entry examinations but not in subsequent ones. 
For UKAEA and BNFL, information was available for ~40% of workers but completeness of 
records was heterogeneous. In France, smoking information was not recorded in early time 
periods. From the mid-1970s, such information was collected more systematically in all 
facilities. Given the heterogeneous data available for each worker’s employment history, and 
no definitive retrospectively-collected data regarding lifetime smoking habits, “never smoker” 
was assigned if any data after the age of 40 indicated the worker never having smoked. “Ever 
smoker” was assigned when any record of smoking appeared in medical records. Where 
neither condition was met (or information was unavailable) “unknown” status was assigned. 
Statistical analysis 
The aim of the study was to derive estimates of the excess relative risk (in terms of the excess 
odds ratio) of lung cancer per gray (Gy) of absorbed dose to the lung from alpha-emitters as a 
group and for plutonium and uranium separately. All information was truncated at the 
reference date. We fitted conditional logistic regression models based on matched sets using 
EPICURE software
30
. The excess OR/Gy was estimated using a mixture model comprising a 
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linear function of radiation dose (both internal and external) and a log-linear function of 
covariates, as is typical in radiation epidemiology, defined: 
          
           
where   is a vector of covariates,    are the covariate parameters to be estimated,   is a vector 
of cumulated doses (both internal and external) minus lag,    is a vector of dose–response 
slopes i.e. the excess OR/Gy to be estimated, and       is a set of stratum parameters 
indicating numbers of cases and controls in each matched set. In common with most modern 
radiation epidemiology studies, we investigated the magnitude of increased cancer risk 
associated with radiation exposure, and therefore followed the convention of reporting 90% 
confidence intervals (CIs) and one-sided p-values. Profile likelihood-based CIs were 
estimated. 
Main analyses were adjusted systematically for external dose, SES, and smoking through 
inclusion in the model—external dose in the linear subterm, all other covariates in the log-
linear subterm—and for age, sex, and facility through matching. Age at start of employment 
and duration of employment were investigated as potential confounders of associations 
between lung cancer and alpha dose, by including them in the model and evaluating whether 
estimates of radiation-induced risk changed by ≥10%. We investigated effect modification of 
the association of lung cancer with alpha dose by attained age, age at start of employment, 
and duration of exposure, and by sex, cohort, smoking, and SES. For each model an 
interaction term was introduced as an exponent of alpha dose. Heterogeneity of risk was 
evaluated using a likelihood ratio test between models including and excluding the 
interaction. Departures from linear dose–response for alpha doses—including quadratic and 
logarithmic transformations in the linear term (logarithm of dose+1 to prevent exclusion of 
zero-dose subjects)—were investigated. We assessed fit using likelihood ratio test 
(dose+dose
2
) and Bayesian information criterion (log(dose+1)). 
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We lagged cumulated doses—both internal and external—by 10 years as is typical in studies 
of nuclear workers and lung cancer
23
. Doses lagged by 5 and 15 years were estimated for 
sensitivity analysis. Other sensitivity analyses included: no adjustment for SES or smoking, 
restricting to men, and exploring heterogeneity among cohorts by running models that omitted 
cohorts one by one. The highly skewed dose data (a large proportion of workers had zero or 
near-zero doses) precluded extensive categorical analysis: four categories were defined based 
on inspection of histograms of dose. 
Results 
In total, 553 cases of lung cancer and 1333 controls were included (Table 2); nine controls 
subsequently became cases. 67% of subjects were ≥65 years old at reference date. Most began 
employment before 1965, ~35% before 1955. Mean date of death was 1989 (median: 1988, 
standard deviation: 10.5). BNFL contributed the largest number of subjects (339 cases; 1010 
controls). 
Distributions of internal alpha doses and photon doses were highly positively skewed (eTable 
2; http://links.lww.com/EDE/B205). Median positive alpha dose to the lung from all 
radionuclides was 2.43mGy (mean: 8.13mGy; maximum: 316mGy; interquartile range width 
(IQRw): 7.76mGy). Median positive alpha doses were 1.27mGy for plutonium (mean: 
5.09mGy; maximum: 110mGy; IQRw: 4.27mGy) and 2.17mGy for uranium (mean: 6.45mGy; 
maximum: 302mGy; IQRw: 5.93mGy). The number of subjects with positive doses was 711 
for plutonium, 1409 for uranium, and 56 for other alpha-emitters. 
Median total alpha doses were highest to BBsec and lowest to BBbas (eFigure 1; 
http://links.lww.com/EDE/B205). Regional doses were highly correlated (Spearman’s rho 
≥0.93 for uranium and plutonium). Ranges and medians of average lung doses generated 
using the alternative weighting scheme were similar (eFigure 2; 
http://links.lww.com/EDE/B205). 
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We found a dose–response relationship for total alpha dose: the excess OR/Gy adjusted for 
external dose, smoking and SES was 11 (90% CI: 2.6; 24) (Table 3). The excess OR/Gy for 
plutonium and uranium adjusted for external dose, smoking, and SES were 50 (90% CI: 17; 
106) and 5.3 (90% CI: -1.9; 18), respectively. Although CIs were wide and overlapped, we 
demonstrated a difference between deviances of models (adjusted for SES, smoking status, 
and photon dose) of combined uranium and plutonium doses and of the two doses separately 
(likelihood ratio test p-value = 0.03). Repeating the analysis for plutonium omitting the seven 
subjects with plutonium dose ≥50mGy gave an excess OR/Gy of 35 (90% CI: 3.5; 88), which 
was lower but statistically compatible with the main plutonium result. No dose–response 
relationship was found for external radiation dose: excess OR/Gy adjusted for smoking and 
SES was -0.38 (90% CI: -0.58; 0.14) (Table 3). 
Most subjects smoked during their lifetime (84% of cases; 62% of controls). Few workers 
never smoked (1% of cases; 4% of controls). Smoking status was unknown for 17% of cases 
and 38% of controls. Odds ratios of lung cancer due to smoking were 9.2 (90% CI: 4, 21) for 
ever smokers and 2.5 (90% CI: 1.1, 5.9) for those of unknown smoking status (eTable 3; 
http://links.lww.com/EDE/B205).  
Removing SES or smoking from the model (eTable 4; http://links.lww.com/EDE/B205) led to 
≥10% change in excess OR/Gy for total alpha, uranium and plutonium doses (with the 
exception of SES for plutonium) suggesting that both variables confound associations 
between lung cancer and alpha dose. Reclassification of SES into two groups resulted in little 
change to the risk estimates (eTable 5; http://links.lww.com/EDE/B205).  
We found no evidence for effect modification of total alpha dose by smoking (p-value: 0.35), 
attained age (p-value: >0.50), age at start of employment (p-value: >0.50), SES (p-value: 
0.08), cohort (maximum likelihood estimate for some parameters could not be calculated), or 
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duration of employment (p-value: >0.50). Similarly, no effect modification by any covariate 
was identified for dose from plutonium or uranium individually. 
We detected no evidence of departures from linearity in the associations for total alpha, 
plutonium or uranium. Likelihood ratio tests indicated that the fits of models of dose+dose
2
 
were no improvement over linear models for total alpha (p-value: 0.12), plutonium (p-value: 
0.07), and uranium (p-value: 0.14). Information criteria also indicated that fits of models of 
log(dose+1) were no improvement over linear models of dose for total alpha (Bayesian 
information criterion 1203.72 vs 1203.57 for linear dose model), plutonium (Bayesian 
information criterion 1199.54 vs 1199.44), and uranium (Bayesian information criterion 
1208.31 vs 1208.25).  
Results of categorical analyses are plotted in Figure 1. For plutonium, the excess OR for the 
highest category was very high, but based on small numbers of subjects (Table 4), with very 
wide CIs that just include the estimate from the model using the continuous form of the 
exposure variable. Sensitivity analyses were carried out with reference categories of zero 
dose: patterns of risk estimates for all internal dose variables were similar to those observed in 
the main analyses (eTable 6; http://links.lww.com/EDE/B205). 
Sensitivity analyses of 5- and 15-year lags produced excess OR/Gy similar to those for 10-
year lags (eTable 7; http://links.lww.com/EDE/B205). Restricting to males (n=1863) gave an 
excess OR/Gy for total alpha dose of 11 (90% CI: 2.6; 24), essentially identical the main 
analysis result. Numbers were too low to restrict to females. 
Estimates of excess OR/Gy for individual lung regions were heterogeneous, particularly for 
total alpha dose (eTable 8; http://links.lww.com/EDE/B205). Generally, however, CIs on the 
dose–response estimates were wide and overlapping. Deviances of models of excess OR/Gy 
of regional alpha doses were consistently lowest for the AI region for all nuclides. Although 
median average lung doses were similar to ICRP weighted lung doses (analyses restricted to 
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UK cohorts as doses to individual lung regions were not available elsewhere), the risk 
estimates for the two sets of doses differed although CIs were wide and overlapped (eTable 9; 
http://links.lww.com/EDE/B205). Differences between the ratios of the risk estimates for 
plutonium versus uranium for individual regions of the lung were small (eTable 8; 
http://links.lww.com/EDE/B205). Risks for plutonium were greater than those for uranium by 
factors of ~7 (BBbas) to ~15 (bb). Risk estimates for plutonium using average lung dose were 
~80% of those estimated using the ICRP weighted dose, compared to ~200% for uranium. 
Risks for total alpha dose were higher for average lung dose than ICRP weighted dose. For all 
dose indices, however, CIs were wide and the results obtained using either weighting system 
are similar.  
Discussion 
This multinational case–control study, combining data from those European nuclear industry 
cohorts with substantial numbers of workers exposed to uranium and/or plutonium, is the first 
large-scale study in which lung doses from both nuclides have been estimated using common 
dosimetric models.  
We found strong evidence that internal exposure to alpha-emitters in the lung increases lung 
cancer risk even at the low doses experienced by nuclear industry workers. A linear model 
proved adequate to describe the shape of dose–response for total alpha, plutonium, and 
uranium doses. External radiation dose did not confound these associations. Smoking and 
SES confounded these associations; the degree to which confounding by smoking was 
controlled was potentially limited by a low proportion of lifetime non-smokers and relatively 
high proportion of subjects for which definitive smoking data were not available (eTable 3; 
http://links.lww.com/EDE/B205). 
In radionuclide-specific analyses, excess OR/Gy were higher for plutonium than for uranium. 
Although CIs associated with estimates for plutonium and uranium were wide and 
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overlapped, the difference in the estimates was statistically significant. Given uncertainties in 
doses
31
, we cannot draw clear conclusions regarding this difference. Also, since the dosimetry 
protocol was agreed, modifications to the HRTM have been recommended
32
 and proposals 
submitted for updated lung solubility parameters for plutonium and uranium compounds 
which might differentially affect doses. Although impacts of these modifications were 
considered in an uncertainty analysis
33
, it would be useful to estimate risk in this population 
using dosimetry including the updated model, and to explore the influence on risk estimates 
of individual-level dosimetric information, such as numbers of bioassays, bioassay data below 
detection limits, solubility assumptions, and calculated intakes.  
Our estimate of excess OR/Gy for total alpha dose is higher than, but compatible with, that of 
previous studies of prolonged exposure to alpha-emitters (Table 5), namely for radon 
exposure in the French uranium miners cohort (FUMC)
28
and for plutonium in the MWC
11
, 
where doses were higher than in our study. The risk estimates in the present study for 
plutonium dose—and specifically for male smokers, for comparison with the MWC—are 
higher than those reported for the MWC
11,22,34
. The reasons for this are unclear, although 
differences between the current study cohorts and MWC in terms of monitoring regimes, 
dosimetry and associated uncertainties, distributions of dose, and potential confounding by 
occupational carcinogens may play a role. The dosimetry used in our study was based on 
more extensive individual biomonitoring data than MWC which led to more accurate (though 
still uncertain) dose estimates, particularly at low doses
25
. Our findings are particularly 
important as other studies of populations internally-exposed to plutonium at doses lower than 
those in the MWC
12,14,35,36
 have not provided clear evidence of increased risk of lung cancer 
with increasing plutonium dose
11
. Using a wR of 20 to express risk in terms of equivalent dose 
to the lung in Sv, our estimates are compatible with those of the atomic bomb survivors
1
. We 
were unable to compare our results with many underground miner studies that present risk in 
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terms of working level months. The FUMC study, however, reported ERR/Gy for lung cancer 
mortality and lung alpha doses of 4.5 (95% CI: 1.3; 11)
28
, which is compatible with our 
results for total alpha dose.  
We found no clear evidence of effect modification by age at start of employment, or duration 
of employment, although the generally low doses meant we had little statistical power to test 
for this. The similarity of results for different lags reflects much of the exposure having 
occurred many years before reference dates (mainly before the 1960s). 
Although we found no evidence of effect modification by smoking, an excess OR/Gy of 7.2 
(90% CI: -0.3, 21) was estimated for total alpha dose (adjusted for SES) in an analysis 
restricted to smokers, which indirectly suggests a similar pattern to that observed in the 
MWC, cohorts of uranium miners, residents exposed to environmental radon and atomic 
bomb survivors
37
, where the modifying effect of smoking on radiation is sub-multiplicative. 
We found no clear evidence of effect modification by cohort. We could not estimate excess 
OR/Gy for some cohorts individually due to small numbers: models for Belgium, France and 
UKAEA failed to converge; effect measures for AWE and BNFL individually were 
imprecise, prohibiting interpretation (results for BNFL in eTable 10; 
http://links.lww.com/EDE/B205). However, heterogeneities in risk estimates observed when 
omitting cohorts one-by-one (eTable 11; http://links.lww.com/EDE/B205) suggest differences 
in risks among them. Omitting Belgium, France or UKAEA had a limited impact on excess 
OR/Gy for total alpha, plutonium or uranium. Omitting both Belgium and France (see ICRP 
weighted lung dose estimates in eTable 9; http://links.lww.com/EDE/B205) also had limited 
impact. Omitting AWE decreased excess OR/Gy for total alpha, plutonium and uranium 
doses. It appears that AWE subjects with relatively higher doses may be influential in the 
analyses. Omitting BNFL had little impact on excess OR/Gy for plutonium dose, but 
increased excess OR/Gy for uranium dose (and subsequently for total alpha dose). Some of 
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the heterogeneity may result from subtle differences in matching: although controls were 
matched on facility in all cohorts, in BNFL this resulted in a tendency to match on 
radionuclide (Sellafield workers were typically exposed only to plutonium, workers at 
Springfields only to uranium). This would potentially reduce contrasts in dose between cases 
and their controls and lead to attenuation of dose–response. Relatively low plutonium doses 
and relatively high uranium doses at BNFL compared to AWE would explain why such 
attenuation would only affect the uranium excess OR/Gy. Also, the plutonium and uranium 
materials to which each cohort was predominantly exposed depended upon the facilities that 
the cohort covered. For example, exposures in the BNFL cohort were predominantly to 
soluble plutonium materials whereas AWE workers were mainly exposed to insoluble 
plutonium materials. While the effect that different material types have on lung dose was 
taken into account in the dose assessment process, it is possible that some systematic bias in 
dose due to material type remained that would manifest itself on a cohort basis
6,25
. 
Information on non-radiological carcinogenic co-exposures such as organic solvents and 
cutting fluids, metals such as beryllium and lithium, and asbestos, was sparse and hence could 
not be included in risk models. 
Differences in excess OR/Gy estimated for lung regions reflect heterogeneity of dose across 
the lung: risk estimates are highest for regions receiving lower doses, and vice versa. It is 
unclear which region, if any, is the most appropriate for assessing risk as our analysis 
considered mortality and lacked information regarding tumour location, type or histology. 
Relatively low deviances of models of excess OR/Gy for total alpha dose to the AI region 
suggest that dose estimation to that region may provide better predictions of lung cancer risk. 
However, given uncertainties in doses, this finding cannot necessarily be considered to 
provide aetiologically meaningful information on risk.  
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A few other cohorts exist in which substantial numbers of workers have been exposed to 
uranium, plutonium and other alpha-emitters, in the former USSR and North America. 
Although studies of uranium and plutonium workers in the USA have been conducted, apart 
from one study of uranium workers
38
, individual dose reconstruction of the type performed 
here has not been conducted. Applying the present methodology to other cohorts would 
potentially provide more precise, comprehensive dose estimates on which to base 
multinational risk analyses. Results could then be compared with those derived from the 
different exposure situation of the MWC, which currently provides the most information on 
risk associated with internal exposures to plutonium. 
Conclusions 
This study is the first in which individual estimates of dose from multiple alpha-emitters have 
been used to estimate the risk of lung cancer mortality in large European cohorts of nuclear 
industry workers. Most subjects in the current study had low lung doses from uranium and/or 
plutonium. We found an increased risk of lung cancer associated with doses from these alpha-
emitters, and although the risk appears greater for plutonium than for uranium, CIs are wide 
and overlapping. Our estimates of the excess OR per Sv for alpha dose are higher than—but 
compatible with—those reported in the FUMC, the MWC and atomic bomb survivors. The 
results lend further support to existing accepted risk estimates associated with internal alpha-
emitters and the radiation protection systems based on them, although uncertainties remain 
and these findings cannot be considered definitive. AC
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Figure legends 
Figure 1– Excess odds ratio (90% confidence intervals) for categorical analysis of alpha dose, 
adjusted for smoking, socioeconomic status and external dose with trend from continuous 
analysis of alpha dose (90% confidence interval). 
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Table 1 
Study populations, study periods and t1 date 
  
Recruitment 
period 
Mortality 
follow-up 
period 
Internal exposure 
monitoring period 
Cohort Study population Start End Start End Pu t1a U t1b 
Belgium 
Employees of SCK·CENc, Belgonucleaire, and 
Belgoprocess 
1969 2002 1969d 2002  1960 1960 
France 
Employees of CEAe and Areva NC (former 
COGEMAf) that never worked as miners, were 
employed at facilities grouped as North (La Hague, 
Brennilis), Paris (Saclay, Fontenay-aux-Roses) and 
South (Pierrelatte, Marcoule, Grenoble, 
Cadarache), were monitored for plutonium or 
uranium through urinalysis, and were monitored for 
external radiation only from 1967 
1950 1994 1968c 2003 1967 1967 
UKAEAg 
All UKAEA workers at Harwell, Winfrith and 
Dounreay 
1946 2002 1946 2002 1970 
1946 
(Harwell) 
1955 
(Dounreay) 
1957 
(Winfrith) 
AWEh All AWE workers employed at Aldermaston 1950 1982 1950 2002 1963 1960  
BNFLi 
All BNFL and UKAEA workers at BNFL Sellafield 
and Springfields monitored for plutonium (post-
1970 exposure) and/or uranium exposure through 
urine analyses  
1949 2002  1949 2002  
1971 
(exposure at 
Sellafield 
only) 
1948 
a The date after which urinalysis data could be used to produce accurate and unbiased dose assessments for plutonium 
b The date after which urinalysis data could be used to produce accurate and unbiased dose assessments for uranium 
c SCK·CEN: Studiecentrum voor Kernenergie·Centre d'Étude de l'énergie Nucléaire 
d Individual causes of death not available before this date 
e CEA: Commissariat à l'énergie atomique 
f COGEMA: Compagnie générale des matières nucélaires 
g UKAEA: United Kingdom Atomic Energy Authority 
h AWE: Atomic Weapons Establishment 
i BNFL: British Nuclear Fuels Limited 
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Table 2 
Distribution of key characteristics of subjects 
 
Cases Controls 
 
(n=553) (n=1333) 
Cohort 
Belgium – SCK·CEN, Belgoprocess and Belgonucleairea 9 19 
France – CEA-COGEMAb 17 36 
UKAEAc 97 108 
UK – AWEd 91 160 
UK – BNFLe 339 1010 
Sex 
Men 544 1319 
Women 9 14 
Age at death of case (reference date) 
<55 54 135 
55-64 132 318 
65-74 242 570 
75+ 125 310 
Year of first exposure to alpha-emitters (dose > 0mGy)f 
<1955 167 496 
1955-64 179 417 
1965-74 99 167 
1975+ 107 250 
Year of death of case (reference date) 
<1975 75 202 
1975-1985 139 322 
1985-1995 191 451 
>1995 148 358 
Socioeconomic status 
All centres except BNFL 
1 (unskilled) 32 82 
2 (partly skilled) 12 33 
3 (skilled manual and non-manual) 60 78 
4 (intermediate and professional) 110 130 
BNFL 
5 (industrial) 301 805 
6 (non-industrial) 38 205 
Smoking 
Never 6 48 
Ever 457 802 
Unknown  90 483 
a SCK·CEN: Studiecentrum voor Kernenergie·Centre d'Étude de l'énergie Nucléaire 
b CEA: Commissariat à l'énergie atomique; COGEMA: Compagnie générale des matières nucélaires 
c UKAEA: United Kingdom Atomic Energy Authority 
d AWE: Atomic Weapons Establishment 
e BNFL: British Nuclear Fuels Limited 
f n = 1882: three controls and one case have no dose recorded for study period 
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Table 3 
Excess odds ratio (EOR) per Gy for lung cancer – matched on sex, age and cohort, lag of 10 years 
  EOR/Gy 90% CIa 
Unadjusted models 
Total alpha dose 13 4.3 27 
Plutonium alpha dose 44 14 92 
Uranium alpha dose 8 -0.42 21 
External dose -0.36 <0b 0.09 
Models adjusted only for external dose 
Total alpha dose 14 4.9 27 
External dose -0.41 <0b -0.00 
Plutonium alpha dose 43 15 90 
External dose -0.39 -0.57 0.03 
Uranium alpha dose 8.7 -0.01 22 
External dose -0.38 -0.58 0.05 
Fully adjusted modelsc 
Total alpha dose 11 2.6 24 
External dose -0.43 -0.61 0.04 
Plutonium alpha dose 50 17 106 
External dose -0.4 -0.58 0.06 
Uranium alpha dose 5.3 -1.9 18 
External dose -0.39 -0.59 0.1 
Plutonium alpha dose 49 16 106 
Uranium alpha dose  4.2 -2.5 17 
External dose -0.44 -0.6 0.04 
Plutonium alpha dose 49 16 106 
Uranium alpha dose 4.2 -2.5 17 
Other radionuclides alpha dose 3.7 -3 42 
External dose -0.44 -0.6 0.04 
External dose -0.38 -0.58 0.14 
All analyses for 553 cases and 1333 controls; alpha doses and external doses 
included in linear subterm of all models. a Confidence interval (CI) based on 
likelihood profile. b <0: lower CI is on boundary of parameter space (1/max 
dose). c Adjusted for smoking and socioeconomic status (loglinear subterm). 
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Table 4 
Distribution of subjects by dose category and results of categorical analysis, adjusted for external dose, 
socioeconomic status and smoking, 10-year lag. 
Dose Dose levels (mGy) Cases Controls Excess odds ratio 90% CIb 
Total alpha dose 
[0,10]a 439 1081 0 - - 
(10 25] 61 178 -0.23 -0.43 0.02 
(25 50] 31 58 0.38 -0.09 1.1 
(50 ∞] 22 16 1.3 0.25 3.5 
Plutonium alpha dose 
[0, 10]a 507 1271 0 - - 
(10,25] 30 53 0.07 -0.33 0.73 
(25,50] 10 8 3.2 0.56 11 
(50,∞] 6 1 25 3.2 341 
Uranium alpha dose 
[0, 10]a 491 1161 0 - - 
(10, 25] 33 126 -0.31 -0.52 -0.03 
(25, 50] 19 39 0.29 -0.21 1.1 
(50, ∞] 10 7 0.60 -0.34 3 
Other radionuclides  
alpha dose 
[0, 10]a 545 1323 0 - - 
(10, 25] 4 1 11 1 143 
(25, 50] 1 5 -0.49 -0.95 1.6 
(50, ∞] 3 4 0.45 -0.64 4.8 
External dosec 
[0, 100]a 448 1059 0 - - 
(100, 250] 64 137 -0.06 -0.32 0.28 
(250, 500] 25 82 -0.43 -0.66 -0.06 
(500, ∞] 16 55 -0.37 -0.69 0.03 
a Reference category.  
b 90% confidence interval (CI) based on likelihood profile.  
c Adjusted only for socioeconomic status and smoking 
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Table 5 
Comparison of current study results with other studies 
 
Study 
Radionuclide / 
radiation 
n 
cases 
Mean dose of 
subjects 
Excess relative 
risk/Gy or Sva 
Confidence 
interval 
Lung absorbed 
doses 
Current study U + Pu + External 553 7.42 mGy 11 2.6b 24b 
    Malesc U + Pu + External 544 7.47 mGy 11 2.6b 24b 
    Smokersd U + Pu + External 457 8.05 mGy 7.2 -0.27b 21b 
    Malesc Pu + External 544 1.92 mGy 48 16b 102b 
    Smokersd Pu + External 457 1.82 mGy 30 0.03b 93b 
    Male smokersd Pu + External 451 1.81 mGy 29 -0.39b 91b 
Mayak (Gilbert et al. 2013): 
    Males Pu 446 93 mGy 7.4 5e 11e 
    Females Pu 40 165 mGy 24 11e  56e 
French Uranium 
miners (Rage et al. 
2012) 
U + External + Rn 66 78 mGy 4.5 1.3b 11b 
Lung equivalent 
doses (RBE=20) 
Current study U + Pu 553 148 mSv 0.55 0.13b 1.2b 
Atomic bomb 
survivorsf 
External 219 600 mGy 0.30 0.08b 0.56b 
Mayak Pu 486 1980 mSv 0.35 0.24e 0.5e 
French uranium 
miners 
U + Rn 66 1560 mSv 0.22 0.06e 0.54e 
a Excess odds ratio for current case-control study. b 90% confidence interval. c Adjusted for socioeconomic status and 
smoking. d Adjusted for socioeconomic status e 95% confidence interval. f Restricted to males of working age (20 to 65) – 
authors’ analysis of RERF LSS Report 14 data (Ozasa et al. 2012). 
Ozasa, K. et al., 2012. Studies of the Mortality of Atomic Bomb Survivors , Report 14 , 1950 – 2003 : 
An Overview of Cancer and Noncancer Diseases. Radiat Res, 243(3), pp.229–243.  
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Figure 1 
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